SE502644C2 - Vasoaktiva vasotocinderivat - Google Patents

Vasoaktiva vasotocinderivat

Info

Publication number: SE502644C2
Authority: SE; Sweden
Prior art keywords: hmp; vasotocin; hgn; derivatives; vasotocin derivatives
Prior art date: 1990-02-27

Application number

SE9000691A

Other languages

English (en)

Swedish (sv)

Other versions

SE9000691D0 (sv

SE9000691L (sv

Inventor

Carl-Johan Aurell

Per Melin

Anders Nilsson

Jerzy Trojnar

Original Assignee

Ferring Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-02-27

Filing date

1990-02-27

Publication date

1995-11-27

1990-02-27 Application filed by Ferring Ab filed Critical Ferring Ab

1990-02-27 Priority to SE9000691A priority Critical patent/SE502644C2/sv

1990-02-27 Publication of SE9000691D0 publication Critical patent/SE9000691D0/xx

1991-02-20 Priority to IL9729891A priority patent/IL97298A/en

1991-02-26 Priority to US07/923,895 priority patent/US5459236A/en

1991-02-26 Priority to EP91905375A priority patent/EP0517778B1/fr

1991-02-26 Priority to DK91905375.1T priority patent/DK0517778T3/da

1991-02-26 Priority to DE69119409T priority patent/DE69119409T2/de

1991-02-26 Priority to AU73424/91A priority patent/AU633198B2/en

1991-02-26 Priority to MC91SE9100154D priority patent/MC2254A1/fr

1991-02-26 Priority to ES91905375T priority patent/ES2089196T3/es

1991-02-26 Priority to IE64891A priority patent/IE62345B1/en

1991-02-26 Priority to CA002076749A priority patent/CA2076749C/fr

1991-02-26 Priority to KR1019920702039A priority patent/KR0171614B1/ko

1991-02-26 Priority to PCT/SE1991/000154 priority patent/WO1991013092A1/fr

1991-02-26 Priority to JP3505030A priority patent/JP2957275B2/ja

1991-02-26 Priority to AT91905375T priority patent/ATE137764T1/de

1991-02-26 Priority to HU9202748A priority patent/HU215121B/hu

1991-02-26 Priority to SU5052869/04A priority patent/RU2067586C1/ru

1991-08-28 Publication of SE9000691L publication Critical patent/SE9000691L/

1992-08-26 Priority to NO92923333A priority patent/NO923333L/no

1992-08-26 Priority to FI923820A priority patent/FI109703B/fi

1995-11-27 Publication of SE502644C2 publication Critical patent/SE502644C2/sv

Links

OXDZADMCOWPSOC-UHFFFAOYSA-N Argiprestocin Chemical class N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 OXDZADMCOWPSOC-UHFFFAOYSA-N 0.000 title claims abstract description 14
230000002227 vasoactive effect Effects 0.000 title description 2
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
OLQOVQTWRIJPRE-UHFFFAOYSA-N 3-mercaptolactic acid Chemical group SCC(O)C(O)=O OLQOVQTWRIJPRE-UHFFFAOYSA-N 0.000 claims abstract description 5
238000002360 preparation method Methods 0.000 claims description 6
150000008574 D-amino acids Chemical class 0.000 claims description 3
239000003085 diluting agent Substances 0.000 claims description 3
229910052739 hydrogen Inorganic materials 0.000 claims description 3
239000004480 active ingredient Substances 0.000 claims description 2
239000000654 additive Substances 0.000 claims description 2
238000007911 parenteral administration Methods 0.000 claims description 2
YZJSUQQZGCHHNQ-BYPYZUCNSA-N (2s)-6-amino-2-azaniumyl-6-oxohexanoate Chemical group OC(=O)[C@@H](N)CCCC(N)=O YZJSUQQZGCHHNQ-BYPYZUCNSA-N 0.000 claims 2
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 1
125000000539 amino acid group Chemical group 0.000 claims 1
230000000694 effects Effects 0.000 abstract description 12
-1 L-2-aminobutyryl Chemical group 0.000 abstract description 3
230000002035 prolonged effect Effects 0.000 abstract description 2
125000001980 alanyl group Chemical group 0.000 abstract 1
230000036772 blood pressure Effects 0.000 description 12
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
230000002686 anti-diuretic effect Effects 0.000 description 8
108090000765 processed proteins & peptides Proteins 0.000 description 8
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
150000001413 amino acids Chemical class 0.000 description 7
239000000047 product Substances 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
239000000126 substance Substances 0.000 description 6
238000012360 testing method Methods 0.000 description 6
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 5
RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 4
239000008280 blood Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
YZJSUQQZGCHHNQ-UHFFFAOYSA-N Homoglutamine Chemical group OC(=O)C(N)CCCC(N)=O YZJSUQQZGCHHNQ-UHFFFAOYSA-N 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
230000008878 coupling Effects 0.000 description 3
238000000034 method Methods 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
239000011347 resin Substances 0.000 description 3
229920005989 resin Polymers 0.000 description 3
239000000243 solution Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
101100305924 Caenorhabditis elegans hoe-1 gene Proteins 0.000 description 2
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
OGNSCSPNOLGXSM-UHFFFAOYSA-N L-2,4-diaminobutyric acid group Chemical group NC(C(=O)O)CCN OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
208000001089 Multiple system atrophy Diseases 0.000 description 2
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
206010031127 Orthostatic hypotension Diseases 0.000 description 2
208000005735 Water intoxication Diseases 0.000 description 2
239000003160 antidiuretic agent Substances 0.000 description 2
229940124538 antidiuretic agent Drugs 0.000 description 2
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
230000000740 bleeding effect Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
238000001514 detection method Methods 0.000 description 2
229910000040 hydrogen fluoride Inorganic materials 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
239000007788 liquid Substances 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
238000012453 sprague-dawley rat model Methods 0.000 description 2
UHPQFNXOFFPHJW-UHFFFAOYSA-N (4-methylphenyl)-phenylmethanamine Chemical compound C1=CC(C)=CC=C1C(N)C1=CC=CC=C1 UHPQFNXOFFPHJW-UHFFFAOYSA-N 0.000 description 1
YAFIBTDNARUFOG-UHFFFAOYSA-N 2-hydroxy-2-sulfanylpropanoic acid Chemical compound CC(O)(S)C(O)=O YAFIBTDNARUFOG-UHFFFAOYSA-N 0.000 description 1
125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
101800001144 Arg-vasopressin Proteins 0.000 description 1
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
239000004131 EU approved raising agent Substances 0.000 description 1
150000008575 L-amino acids Chemical class 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
108010004977 Vasopressins Proteins 0.000 description 1
102000002852 Vasopressins Human genes 0.000 description 1
150000003862 amino acid derivatives Chemical class 0.000 description 1
239000003708 ampul Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229910052804 chromium Inorganic materials 0.000 description 1
239000011651 chromium Substances 0.000 description 1
229940125782 compound 2 Drugs 0.000 description 1
229940126214 compound 3 Drugs 0.000 description 1
229940125898 compound 5 Drugs 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000029142 excretion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
239000011630 iodine Substances 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
IOPLHGOSNCJOOO-UHFFFAOYSA-N methyl 3,4-diaminobenzoate Chemical compound COC(=O)C1=CC=C(N)C(N)=C1 IOPLHGOSNCJOOO-UHFFFAOYSA-N 0.000 description 1
239000000203 mixture Substances 0.000 description 1
WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
239000012071 phase Substances 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
ZERULLAPCVRMCO-UHFFFAOYSA-N sulfure de di n-propyle Natural products CCCSCCC ZERULLAPCVRMCO-UHFFFAOYSA-N 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000011282 treatment Methods 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
229960003726 vasopressin Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/16—Oxytocins; Vasopressins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Saccharide Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Steroid Compounds (AREA)

SE9000691A 1990-02-27 1990-02-27 Vasoaktiva vasotocinderivat SE502644C2 (sv)

Priority Applications (19)

Application Number	Priority Date	Filing Date	Title
SE9000691A SE502644C2 (sv)	1990-02-27	1990-02-27	Vasoaktiva vasotocinderivat
IL9729891A IL97298A (en)	1990-02-27	1991-02-20	Vasoactive vasotocin derivatives and pharmaceutical compositions containing them
SU5052869/04A RU2067586C1 (ru)	1990-02-27	1991-02-26	Производные вазотоцина
ES91905375T ES2089196T3 (es)	1990-02-27	1991-02-26	Derivados de la vasotocina vasoactiva.
KR1019920702039A KR0171614B1 (ko)	1990-02-27	1991-02-26	혈관활성 바소토신 유도체
DK91905375.1T DK0517778T3 (da)	1990-02-27	1991-02-26	Vasoaktive vasotocinderivater
DE69119409T DE69119409T2 (de)	1990-02-27	1991-02-26	Vasoaktive derivate des vasotocins
AU73424/91A AU633198B2 (en)	1990-02-27	1991-02-26	Vasoactive vasotocin derivatives
MC91SE9100154D MC2254A1 (fr)	1990-02-27	1991-02-26	Derives de la vasotocine
US07/923,895 US5459236A (en)	1990-02-27	1991-02-26	Vasoactive vasotocin derivatives
IE64891A IE62345B1 (en)	1990-02-27	1991-02-26	Vasoactive vasotocin derivatives
CA002076749A CA2076749C (fr)	1990-02-27	1991-02-26	Derives vasoactifs de la vasotocine
EP91905375A EP0517778B1 (fr)	1990-02-27	1991-02-26	Derives de vasotocine vasoactifs
PCT/SE1991/000154 WO1991013092A1 (fr)	1990-02-27	1991-02-26	Derives de vasotocine vasoactifs
JP3505030A JP2957275B2 (ja)	1990-02-27	1991-02-26	血管作動性バソトシン誘導体
AT91905375T ATE137764T1 (de)	1990-02-27	1991-02-26	Vasoaktive derivate des vasotocins
HU9202748A HU215121B (hu)	1990-02-27	1991-02-26	Eljárás vazotocinszármazékok és ilyen vegyületeket tartalmazó gyógyászati készítmények előállítására
FI923820A FI109703B (fi)	1990-02-27	1992-08-26	Menetelmä vasoaktiivisten vasotosiinijohdannaisten valmistamiseksi
NO92923333A NO923333L (no)	1990-02-27	1992-08-26	Vasoaktive vasotocinderivater

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE9000691A SE502644C2 (sv)	1990-02-27	1990-02-27	Vasoaktiva vasotocinderivat

Publications (3)

Publication Number	Publication Date
SE9000691D0 SE9000691D0 (sv)	1990-02-27
SE9000691L SE9000691L (sv)	1991-08-28
SE502644C2 true SE502644C2 (sv)	1995-11-27

Family

ID=20378692

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE9000691A SE502644C2 (sv)	1990-02-27	1990-02-27	Vasoaktiva vasotocinderivat

Country Status (19)

Country	Link
US (1)	US5459236A (fr)
EP (1)	EP0517778B1 (fr)
JP (1)	JP2957275B2 (fr)
KR (1)	KR0171614B1 (fr)
AT (1)	ATE137764T1 (fr)
AU (1)	AU633198B2 (fr)
CA (1)	CA2076749C (fr)
DE (1)	DE69119409T2 (fr)
DK (1)	DK0517778T3 (fr)
ES (1)	ES2089196T3 (fr)
FI (1)	FI109703B (fr)
HU (1)	HU215121B (fr)
IE (1)	IE62345B1 (fr)
IL (1)	IL97298A (fr)
MC (1)	MC2254A1 (fr)
NO (1)	NO923333L (fr)
RU (1)	RU2067586C1 (fr)
SE (1)	SE502644C2 (fr)
WO (1)	WO1991013092A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6828415B2 (en)	1993-02-19	2004-12-07	Zentaris Gmbh	Oligopeptide lyophilisate, their preparation and use
PT710243E (pt) *	1993-06-29	2000-11-30	Ferring Bv	Sintese melhorada de peptidos ciclicos.
JO2937B1 (en) *	2004-08-11	2016-03-15	فيرينغ.بي.في	Tight muscles of the peptide vascular tensioner receptor
KR101194586B1 (ko) *	2006-02-10	2012-10-25	훼링 비.브이.	신규 화합물
WO2009037586A2 (fr)	2007-08-14	2009-03-26	Ferring B.V.	Utilisation d'agonistes peptidiques du récepteur de la vasopressine
RU2454426C1 (ru) *	2011-04-06	2012-06-27	Федеральное государственное образовательное учреждение высшего профессионального образования Санкт-Петербургский государственный университет	Пептид калий-уретический
KR101304427B1 (ko)	2011-04-12	2013-09-05	한국과학기술연구원	재사용이 용이한 기공체 - 위성 나노입자 복합체 및 그 제조방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1246055A (fr) *	1980-03-24	1988-12-06	Joseph H. Cort	Hormonogenes substitues de la vasopressine et ses analogues synthetiques
SE469473B (sv) *	1987-10-07	1993-07-12	Ferring Ab	Vasoaktiva peptider

1990
- 1990-02-27 SE SE9000691A patent/SE502644C2/sv not_active IP Right Cessation
1991
- 1991-02-20 IL IL9729891A patent/IL97298A/en not_active IP Right Cessation
- 1991-02-26 DE DE69119409T patent/DE69119409T2/de not_active Expired - Fee Related
- 1991-02-26 AT AT91905375T patent/ATE137764T1/de not_active IP Right Cessation
- 1991-02-26 CA CA002076749A patent/CA2076749C/fr not_active Expired - Fee Related
- 1991-02-26 ES ES91905375T patent/ES2089196T3/es not_active Expired - Lifetime
- 1991-02-26 AU AU73424/91A patent/AU633198B2/en not_active Ceased
- 1991-02-26 RU SU5052869/04A patent/RU2067586C1/ru not_active IP Right Cessation
- 1991-02-26 KR KR1019920702039A patent/KR0171614B1/ko not_active Expired - Fee Related
- 1991-02-26 HU HU9202748A patent/HU215121B/hu not_active IP Right Cessation
- 1991-02-26 WO PCT/SE1991/000154 patent/WO1991013092A1/fr not_active Ceased
- 1991-02-26 US US07/923,895 patent/US5459236A/en not_active Expired - Fee Related
- 1991-02-26 MC MC91SE9100154D patent/MC2254A1/fr unknown
- 1991-02-26 JP JP3505030A patent/JP2957275B2/ja not_active Expired - Fee Related
- 1991-02-26 DK DK91905375.1T patent/DK0517778T3/da active
- 1991-02-26 IE IE64891A patent/IE62345B1/en not_active IP Right Cessation
- 1991-02-26 EP EP91905375A patent/EP0517778B1/fr not_active Expired - Lifetime
1992
- 1992-08-26 NO NO92923333A patent/NO923333L/no unknown
- 1992-08-26 FI FI923820A patent/FI109703B/fi active

Also Published As

Publication number	Publication date
NO923333L (no)	1992-10-16
CA2076749C (fr)	2001-02-20
JPH05504575A (ja)	1993-07-15
DE69119409D1 (de)	1996-06-13
RU2067586C1 (ru)	1996-10-10
WO1991013092A1 (fr)	1991-09-05
EP0517778B1 (fr)	1996-05-08
FI109703B (fi)	2002-09-30
SE9000691D0 (sv)	1990-02-27
SE9000691L (sv)	1991-08-28
IE62345B1 (en)	1995-01-25
HUT61580A (en)	1993-01-28
DE69119409T2 (de)	1996-09-05
AU7342491A (en)	1991-09-18
US5459236A (en)	1995-10-17
EP0517778A1 (fr)	1992-12-16
JP2957275B2 (ja)	1999-10-04
DK0517778T3 (da)	1996-08-19
IL97298A (en)	1995-08-31
ES2089196T3 (es)	1996-10-01
KR0171614B1 (ko)	1999-02-01
IE910648A1 (en)	1991-08-28
ATE137764T1 (de)	1996-05-15
AU633198B2 (en)	1993-01-21
CA2076749A1 (fr)	1991-08-28
MC2254A1 (fr)	1993-03-25
FI923820L (fi)	1992-08-26
HU9202748D0 (en)	1992-12-28
KR920703003A (ko)	1992-12-17
NO923333D0 (no)	1992-08-26
FI923820A0 (fi)	1992-08-26
HU215121B (hu)	1998-09-28
IL97298A0 (en)	1992-05-25

Legal Events

Date	Code	Title	Description
2004-09-28	NUG	Patent has lapsed

Publication	Publication Date	Title
US4766108A (en)	1988-08-23	Tyr-Arg-vasopressin antagonists
US4724229A (en)	1988-02-09	Arg-arg-arg-vasopressin antagonists
US5106834A (en)	1992-04-21	Linear free-sulfhydryl-containing oligopeptide derivatives as antihypertensive agents
SE502644C2 (sv)	1995-11-27	Vasoaktiva vasotocinderivat
EP0438566B1 (fr)	1996-09-25	Antagonistes de substance P
US4481194A (en)	1984-11-06	Des-proline-des-glycine vasopressin antagonists
US4481193A (en)	1984-11-06	Des-proline vasopressin antagonists
US4597901A (en)	1986-07-01	β-indolylalanyl or β-indolylglycinyl vasopressin antagonists
EP0380554B1 (fr)	1993-07-07	Peptides vaso-actifs
FI73225B (fi)	1987-05-29	Foerfarande foer framstaellning av terapeutiskt aktiva derivat av angiotensin-ii, vilka innehaoller i 8-staellningen -hydroxikarboxylsyragrupp.
Gazis et al.	1984	Influence of sarcosine or N‐methylalanine in position 7 on the antagonistic properties of [1‐deaminopenicillamine]‐and [1‐(β‐mercapto‐β, β‐cyclopentylmethylene‐propionic acid)]‐vasopressin
US4719199A (en)	1988-01-12	Diuretic compositions and methods of producing diuresis
Gobbo et al.	1997	Synthesis and biological activities of head‐to‐tail cyclic bradykinin analogues of varying ring size
US4684716A (en)	1987-08-04	Polypeptide intermediates
EP0346068A2 (fr)	1989-12-13	Antagonistes de D-Cys6-vasopressine
US4826813A (en)	1989-05-02	4'-Methyl-β-mercapto-β,β-cyclopentamethylenepropionic acid vasopressin antagonists
EP0234935A2 (fr)	1987-09-02	Composés vasopressine
Manning et al.	1995	Effects of a D-Cys6/L-Cys6 interchange in nonselective and selective vasopressin and oxytocin antagonists
JPS63225399A (ja)	1988-09-20	ペプチド誘導体およびその製造法
AU2024247803A1 (en)	2025-09-18	Long-acting calcitonin analog
EP0154544A2 (fr)	1985-09-11	Antagonistes de de-proline vasopressine